(Q44569389)

English

Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization

scientific article published on 6 May 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Immunogenicity analysis following human immunodeficiency virus recombinant DNA and recombinant vaccinia virus Tian Tan prime-boost immunization (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

0 references

object named as

vaccinia virus

1 reference

based on heuristic

inferred from title

author name string

Cunxia Liu

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Shouwen Du

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Chang Li

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Yuhang Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Maopeng Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Yi Li

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Ronglan Yin

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Xiao Li

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Dayong Ren

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Yanqing Qin

10

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Jingqiang Ren

11

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Ningyi Jin

12

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

publication date

6 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

Science in China. Series C: Life Sciences

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

531-540

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

https://scigraph.springernature.com/pub.10.1007/s11427-013-4484-2

0 references

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Improved NYVAC-based vaccine vectors

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Resistance-associated epitopes of HIV-1C-highly probable candidates for a multi-epitope vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Full-length HIV-1 immunogens induce greater magnitude and comparable breadth of T lymphocyte responses to conserved HIV-1 regions compared with conserved-region-only HIV-1 immunogens in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

The design and evaluation of HIV-1 vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Electroporation for DNA immunization: clinical application

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Poxvirus vectors as HIV/AIDS vaccines in humans

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Viral sequence diversity: challenges for AIDS vaccine designs

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

A macaque model of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Immunologic basis of vaccine vectors

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02).

1 reference

https://api.crossref.org/works/10.1007%2FS11427-013-4484-2

21 January 2018

Identifiers

10.1007/S11427-013-4484-2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44569389&oldid=2028425029"